Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 6
2016 17
2017 19
2018 16
2019 21
2020 25
2021 17
2022 15
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 35552245

100 results

Results by year

Filters applied: . Clear all
Page 1
Correlation of 68Ga-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
Duan H, Baratto L, Fan RE, Soerensen SJC, Liang T, Chung BI, Thong AEC, Gill H, Kunder C, Stoyanova T, Rusu M, Loening AM, Ghanouni P, Davidzon GA, Moradi F, Sonn GA, Iagaru A. Duan H, et al. J Nucl Med. 2022 Dec;63(12):1829-1835. doi: 10.2967/jnumed.122.263971. Epub 2022 May 12. J Nucl Med. 2022. PMID: 35552245 Free article.
Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Touijer KA, Michaud L, Alvarez HAV, Gopalan A, Kossatz S, Gonen M, Beattie B, Sandler I, Lyaschenko S, Eastham JA, Scardino PT, Hricak H, Weber WA. Touijer KA, et al. Eur Urol Oncol. 2019 Mar;2(2):166-173. doi: 10.1016/j.euo.2018.08.011. Epub 2018 Sep 22. Eur Urol Oncol. 2019. PMID: 31017093 Free PMC article. Clinical Trial.
Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study.
Beheshti M, Taimen P, Kemppainen J, Jambor I, Müller A, Loidl W, Kähkönen E, Käkelä M, Berndt M, Stephens AW, Minn H, Langsteger W. Beheshti M, et al. Eur Radiol. 2023 Jan;33(1):472-482. doi: 10.1007/s00330-022-08982-2. Epub 2022 Jul 21. Eur Radiol. 2023. PMID: 35864350 Free PMC article. Clinical Trial.
Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI.
Szigeti F, Schweighofer-Zwink G, Meissnitzer M, Hauser-Kronberger C, Hitzl W, Kunit T, Forstner R, Pirich C, Beheshti M. Szigeti F, et al. Mol Imaging Biol. 2022 Feb;24(1):50-59. doi: 10.1007/s11307-021-01650-9. Epub 2021 Sep 14. Mol Imaging Biol. 2022. PMID: 34519966 Free PMC article. Clinical Trial.
Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study.
Schollhammer R, Robert G, Asselineau J, Yacoub M, Vimont D, Balamoutoff N, Bladou F, Bénard A, Hindié E, Gallerande HC, Morgat C. Schollhammer R, et al. J Nucl Med. 2023 Mar;64(3):379-385. doi: 10.2967/jnumed.122.263889. Epub 2022 Sep 2. J Nucl Med. 2023. PMID: 36215569 Free PMC article. Clinical Trial.
Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, McEwan L, Wong D, Delahunt B, Egevad L, Samaratunga H, Brown N, Parkinson R, Roberts MJ, Yaxley JW. Franklin A, et al. BJU Int. 2021 Jan;127(1):71-79. doi: 10.1111/bju.15134. Epub 2020 Sep 7. BJU Int. 2021. PMID: 32524748
100 results